SubHero Banner
Text

Ontruzant® (trastuzumab-dttb) – New biosimilar approval

January 18, 2019 - The FDA approved Samsung Bioepis and Merck’s Ontruzant (trastuzumab-dttb), a biosimilar to Genentech’s Herceptin® (trastuzumab).

Download PDF